Nuclidium Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $134M

  • Investors
  • 12

Nuclidium General Information

Description

Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. The company's platform provides new diagnostic and therapeutic tracers in which specific target molecules will first be detected on the patient's tumor and can be treated with similar chemical properties and the same biological molecular targets, enabling the patients to access affordable and effective personalized treatment.

Contact Information

Website
www.nuclidium.com
Formerly Known As
Swiss Nuclides
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Im Erasmushaus
  • Bäumleingasse 18
  • 4051 Basel
  • Switzerland
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Oncology
Corporate Office
  • Im Erasmushaus
  • Bäumleingasse 18
  • 4051 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuclidium Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 27-May-2026 $134M Completed Clinical Trials - General
3. Grant 27-Jun-2022 Completed Clinical Trials - General
2. Early Stage VC (Series A) 24-Jun-2021 $2.88M $2.88M Completed Clinical Trials - General
1. Grant 21-Sep-2020 $1.18M Completed Startup
To view Nuclidium’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Nuclidium Patents

  • 40

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 29

    Pending

  • Expiring in next 12 mo

Nuclidium Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025300551-A1 Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof Pending 22-Mar-2024
US-20260241047-A1 Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof Pending 22-Mar-2024
WO-2026010658-A2 Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof Pending 22-Mar-2024
WO-2026010658-A3 Fibroblast activation protein-targeting radiopharmaceuticals and uses thereof Pending 22-Mar-2024
WO-2025199536-A1 Fully automated manufacturing and purification of cu-61 and uses thereof Pending 22-Mar-2024 G21G1/0005
To view Nuclidium’s complete patent history, request access »

Nuclidium Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuclidium Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angelini Ventures Corporate Venture Capital Minority
Bayern Kapital Venture Capital Minority
DeepTech & Climate Fonds Venture Capital Minority
Eurazeo Asset Manager Minority
Highlight Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Nuclidium FAQs

  • When was Nuclidium founded?

    Nuclidium was founded in 2017.

  • Where is Nuclidium headquartered?

    Nuclidium is headquartered in Basel, Switzerland.

  • What is the size of Nuclidium?

    Nuclidium has 14 total employees.

  • What industry is Nuclidium in?

    Nuclidium’s primary industry is Biotechnology.

  • Is Nuclidium a private or public company?

    Nuclidium is a Private company.

  • What is Nuclidium’s current revenue?

    The current revenue for Nuclidium is .

  • How much funding has Nuclidium raised over time?

    Nuclidium has raised $137M.

  • Who are Nuclidium’s investors?

    Angelini Ventures, Bayern Kapital, DeepTech & Climate Fonds, Eurazeo, and Highlight Capital are 5 of 12 investors who have invested in Nuclidium.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process